Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TM471-1
- Development stage
- Unknown
- Lead developer
- Zhiwei Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TM471-1 is an investigational, potent, and selective small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) developed by Zhiwei Biopharma (Xinxiang) Co., Ltd. It is primarily being evaluated for the treatment of various B-cell malignancies, including marginal zone lymphoma (MZL), follicular lymphoma, and chronic lymphocytic leukemia. By inhibiting BTK, TM471-1 disrupts B-cell receptor (BCR) signaling, which is crucial for the survival and proliferation of malignant B cells. The drug is currently in Phase 1/2 clinical trials in China, demonstrating potential as a targeted therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on TM471-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TM471-1.